Intravitreal ranibizumab as primary treatment  for neovascular membrane associated with idiopathic  juxtafoveal retinal telangiectasia.
Konstantinidis
Lazaros
L
Mantel
Irmela
I
Zografos
Leonidas
L
Ambresin
Aude
A
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008875:Middle Aged; D000069579:Ranibizumab; D015861:Retinal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D012171:Retinal Vessels / Q000473:pathology; D019233:Retreatment; D013684:Telangiectasis / Q000175:diagnosis / Q000188:drug therapy*; D041623:Tomography, Optical Coherence; D014792:Visual Acuity; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab